Hattie Hayes

1 month ago | optometrytimes.com | Martin Harp |Hattie Hayes

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel). At the date of approval, ENCELTO is the first and only FDA-approved Treatment for MacTel. ENCELTO utilizes an encapsulated cell therapy (ECT) technology designed to continually deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina to assist in slowing the progression of the disease.

1 month ago | ophthalmologytimes.com | Martin Harp |Hattie Hayes

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals for the treatment of Macular Telangiectasia type 2 (MacTel). At the date of approval, ENCELTO is the first and only FDA-approved Treatment for MacTel. ENCELTO utilizes an encapsulated cell therapy (ECT) technology designed to continually deliver therapeutic doses of ciliary neurotrophic factor (CNTF) to the retina to assist in slowing the progression of the disease.

2 months ago | europe.ophthalmologytimes.com | Sheryl Stevenson |Hattie Hayes |Anat Loewenstein

Following the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting, held virtually on February 8, 2025, Anat Loewenstein, MD, shared key takeaways from her presentation. Prof Loewenstein is Professor and Head of Retina, Division of Ophthalmology at Tel Aviv Medical Center, Sydney Fox Chair of Ophthalmology at Tel Aviv University, and President of the Israeli Ophthalmological Society, all in Tel Aviv, Israel.

Jan 16, 2025 | europe.ophthalmologytimes.com | Hattie Hayes

PulseSight Therapeutics SAS, a biotechnology firm based in Paris, France, announced its clinical plan for ocular therapy candidate PST-611, including submission of a Clinical Trial Authorisation (CTA) to French regulatory offices. If approved by the Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), investigators will proceed with a phase I trial assessing safety and tolerability of PST-611.

Jan 14, 2025 | modernretina.com | Hattie Hayes

January 14, 2025Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis). In a press release, Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., announced it would partner with Klinge Biopharma GmbH and Formycon AG in commercializing FYB203, Formycon’s biosimilar candidate to aflibercept (Eylea, Regeneron Pharmaceuticals Inc.).